Skip to content

Clinical study on the effect of Shuhe Granule on "enhancing effect and reducing toxicity" of sedative hypnotic drugs

Clinical study on the effect of Shuhe Granule on "enhancing effect and reducing toxicity" of sedative hypnotic drugs

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082233
Enrollment
Unknown
Registered
2024-03-25
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

Test group:Shuhe Granule,150ml each time with hot water, twice a day for 4 weeks

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) 18 -70 years old. (2) It meets the diagnostic criteria of ICSD-3 chronic insomnia disorder. (3) ISI total score >7 (4) Stable vital signs, clear mind, with a certain ability to express (5) Consistent with Qi and blood disharmony, heart and kidney deficiency syndrome: Sleeplessness, fatigue, fear of cold or wind, cold limbs, palpitations, dizziness, spontaneous sweating, less menstruation, light white lower eyelids or light white with red edges; (6) Those who are taking sedative hypnotics (=4 nights per week) (7) Sign informed consent

Exclusion criteria

Exclusion criteria: (1) Comply with any of the excluded symptoms: a. The lower eyelid is completely red b. Warm hands c. Dry, hard stool d. Thick and greasy fur or dry and rough e. Pulse ratio greater than 5 (2) People who are preparing to become pregnant or during pregnancy or breastfeeding or who need to sleep with their children. (3) Based on the medical history and consultation, the doctor confirms secondary insomnia caused by other diseases. For example: local pain, restless leg syndrome, sleep apnea syndrome, acute and chronic heart failure, chronic obstructive pulmonary disease, acute and chronic bronchitis (4) Patients diagnosed with major depression according to the Patient Depression Screening Scale (PHQ-9) (total score =15) (5) Diagnosis of severe anxiety according to the Generalized Anxiety Disorder Scale (GAD-7) (total score =15) (6) Patients with severe cardiovascular, cerebrovascular, liver, kidney and endocrine system diseases and unstable conditions (7) Those who have suffered from severe mental illness such as major bipolar disorder, schizophrenia, mental retardation, alcohol/substance abuse or dependence, and suicidal tendencies (8) Participants who have participated in other drug clinical trials within the past 30 days

Design outcomes

Primary

MeasureTime frame
Insomnia severity index scale;

Secondary

MeasureTime frame
Pittsburgh sleep quality index;Patient Health Questionnaire-9;Generalized Anxiety Disorder Scale;Fatigue severity scale;Usage of western medicine;

Countries

china

Contacts

Public ContactBiyun Xu

Guangdong Provincial Hospital of Traditional Chinese Medicine

cloudxby@163.com+86 20 8149 9399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026